From Biweekly IV Tubes to a Morning Capsule: Why We Rebuilt an 18-Year PNH Patient Domain

1. Tonight in a Quiet Bedroom: The Lab Sheet Nobody Translated

Somewhere tonight, a twenty-eight-year-old who walked into a clinic for crushing fatigue and dark morning urine is sitting on the edge of a bed staring at a smartphone screen. The hospital portal just released a flow cytometry report full of alien acronyms: FLAER-deficient granulocytes, Type III CD59-negative erythrocytes, LDH elevated, haptoglobin undetectable. One browser tab says the condition is related to bone marrow failure. Another tab mentions blood clots in the liver veins. A third tab quotes a medication price higher than the cost of a house.

Twenty years ago, when patients opened their browser in that same quiet panic, they landed here on pnhdisease.org.

2. Why We Refused to Let an 18-Year Lifeline Become a Broken Link

When the original volunteers launched the PNH Support Group on pnhdisease.org in 2003, there was not a single FDA-approved drug for Paroxysmal Nocturnal Hemoglobinuria. Hematologists could offer only blood transfusions, folate tablets, warfarin, or a high-risk bone marrow transplant. Then came 2007 and eculizumab (Soliris), proving that blocking terminal C5 could stop intravascular hemolysis and save lives. Over the next decade, Johns Hopkins Medicine, Orphanet, Marrowforums, and Spanish/Portuguese HPN blogs linked to pnhdisease.org and its PDF guides.

Yet while the old domain eventually went offline after 2021, the science of PNH underwent a second revolution. Long-acting ravulizumab (Ultomiris, 2018) freed patients from biweekly IV chairs to six infusions a year. Then proximal complement blockade solved the puzzle that C5 inhibitors left behind: pegcetacoplan (Empaveli, 2021) at C3, iptacopan (Fabhalta, Dec 2023) as a twice-daily oral Factor B pill, danicopan (Voydeya, Apr 2024) as an oral Factor D add-on, and crovalimab (Piasky, 2024) as a monthly subcutaneous injection.

Today's patients face a completely new paradox: there are now six remarkable drugs, yet every commercial website is owned by a pharmaceutical manufacturer that can only talk about its own molecule. Nobody puts all six drugs, their extravascular hemolysis trade-offs, their missed-dose breakthrough risks, and their global prices into one honest, independent table.

3. Four Commitments That Govern Every Line on This Desk

• Patient Safety Before Pageviews: If you have PNH and wake up with severe abdominal pain, a thunderclap headache, or a 38.0°C (100.4°F) fever on a complement inhibitor, we do not want you reading articles. Our top banner and ER Physician Triage Card exist to get you immediate ceftriaxone, Doppler imaging, and hematology rescue.
• Decode the Lab Numbers in Plain Language: We built the 60-Second Flow Cytometry & LDH Decoder so no patient ever panics when their RBC clone percentage rises after starting therapy (which simply means their red cells are finally surviving!).
• Zero Commercial Bias Across Drug Classes: Because we accept zero pharmaceutical money, we can state plainly when 8-week IV ravulizumab is the safest choice for someone who forgets daily pills, and when oral iptacopan or subcutaneous pegcetacoplan is transformative for someone trapped at a hemoglobin of 9.0 g/dL by C3d extravascular hemolysis.
• A True Global & Trilingual Coordinate System: A rare disease does not stop at English borders or US insurance networks. Inspired by the 32 Latin American backlinks that pointed to this domain for over a decade and the rapid expansion of PNH reimbursement and transplant centers in China, every single page on pnhdisease.org is crafted natively in English, Spanish, and Simplified Chinese.

4. Honoring the Past, Serving the Next Twenty Years

We do not claim the credit of the 2003-2021 volunteer pioneers who built the original PNH Support Group. Instead, we treat their 18-year digital footprint as an obligation: every historical link to pnh_patient_brochure_v1.pdf, impact_of_mri.pdf, or widespread_abdominal_venous.pdf now lands seamlessly on a meticulously referenced 2026 clinical section.

Read the tables, print the ER Triage Card for your wallet, bring the Complement Inhibitor Matrix to your next hematology appointment, and write to us at [email protected] whenever a new trial or regional reimbursement rule needs to be added to the ledger.